Faster diagnosis. Lower cost. Better patient care.
Progen Diagnostics helps UK and Irish healthcare providers adopt Uromonitor®, a non-invasive molecular urine test supporting bladder cancer surveillance, pathway triage and smarter use of cystoscopy capacity.
Explore Progen Diagnostics
Learn how Progen Diagnostics supports healthcare providers with faster diagnosis, lower cost, better patient care and the adoption of Uromonitor® in bladder cancer surveillance pathways.
Faster Diagnosis
Support earlier pathway decisions and prioritise patients who may need cystoscopy sooner.
Learn moreLower Cost
Reduce avoidable cystoscopy demand and improve use of specialist clinical capacity.
Learn morePatient Care
Create a less invasive, more patient-centred surveillance experience where appropriate.
Learn moreUromonitor
Understand the non-invasive molecular urine test and how it supports clinical decision-making.
Learn moreEvidence
Review clinical evidence, pathway modelling and implementation materials.
Learn moreContact
Speak to Progen Diagnostics about evidence, implementation and adoption.
Get in touchSupporting safe adoption of Uromonitor®
Comprehensive Implementation Support
Progen Diagnostics supports healthcare providers with evidence review, pathway modelling, laboratory workflow, governance planning and implementation support for Uromonitor® adoption.
Clinical evidence review
Helping teams understand the evidence behind Uromonitor®.
Pathway modelling
Supporting cost, capacity and cystoscopy prioritisation discussions.
Laboratory workflow
Helping providers understand sample handling, testing and reporting.
Governance planning
Supporting patient selection, escalation rules and audit.